Khaled Elshazly: Can We Stop Chemotherapy-Induced Thrombocytopenia from Delaying Treatment?
Khaled Elshazly, Head of Oncology Clinical Pharmacists and the IV Admixture Unit at Agouza Hospital, shared a LinkedIn post about a recent article by Hanny Al-Samkari et al., published in The New England Journal of Medicine:
”Breakthrough in cancer care: Can we stop chemotherapy-induced thrombocytopenia (CIT) from delaying treatment?
A major challenge in oncology is having to reduce or delay life-saving chemotherapy because it destroys platelet-producing bone marrow cells. But a new global Phase 3 clinical trial just published in the New England Journal of Medicine (NEJM) offers a highly effective solution.
Led by investigators at Mass General Brigham, the trial evaluated Romiplostim vs. Placebo for Chemotherapy-Induced Thrombocytopenia (CIT).
Here are the game-changing results:
- The Trial: 165 patients (109 on romiplostim, 56 on placebo).
- The Impact: Patients taking romiplostim had a >10-fold lower odds of needing a chemotherapy dose reduction due to CIT.
- Efficacy: A remarkable 84% of patients in the romiplostim group required no chemotherapy dose modifications at all, compared to just 36% in the placebo group.
- Safety: The drug was well-tolerated. While overall adverse events were slightly higher in the treatment group, this primarily reflected the fact that these patients were successfully able to receive higher, un-reduced doses of their multi-agent chemotherapy.
Why this matters:
Romiplostim effectively boosts the bone marrow’s resilience, allowing patients to maintain their critical platelet counts. This means fewer treatment interruptions, optimal chemotherapy dosing, and better overall outcomes for cancer patients.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al-Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 28, 2026, 19:05Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
-
Jun 28, 2026, 19:05Pinar Demirtepe: Not All “Blood Thinners” Are the Same
-
Jun 28, 2026, 19:05Andrea Cesari: Comparing Catheter-Based Reperfusion Strategies for Intermediate-High-Risk PE
-
Jun 28, 2026, 19:02Nassim Emteir: Interpreting TSAT with Ferritin to Guide Iron Deficiency Diagnosis and Treatment
-
Jun 28, 2026, 19:00Andrew Jackson: Predicting PICC-Related Venous Thrombosis in Patients Undergoing Radiotherapy
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients